US appeals court revives suit against Schering-Plough
News | 17 July 2012
In the past, several courts had ruled that pay-for-delay arrangements were permissible as long as the brands and generics agreed that the generic would not stay out of the market for longer than the life of the patent. On Monday, the federal court took ...
Click on the link to read the full article at Washington Post
(This link will open in a new window)
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
